Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - ATOSSA THERAPEUTICS, INC. | s105604_ex32-2.htm |
| EX-32.1 - EXHIBIT 32.1 - ATOSSA THERAPEUTICS, INC. | s105604_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - ATOSSA THERAPEUTICS, INC. | s105604_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - ATOSSA THERAPEUTICS, INC. | s105604_ex31-1.htm |
| EX-22.1 - EXHIBIT 22.1 - ATOSSA THERAPEUTICS, INC. | s105604_ex22-1.htm |
| 10-K/A - 10-K/A - ATOSSA THERAPEUTICS, INC. | s105604_10ka.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Atossa Genetics Inc.
Seattle, Washington
We hereby consent to the incorporation by reference in the Registration Statements on Form S-1 (No. 333-205308, 333-208236, 333-211797 and 333-216031), Form S-3 (No. 333-186248 and 333-192390), and Form S-8 (No. 333-185625 and 333-193952) of Atossa Genetics Inc. of our report dated March 16, 2017 (except as to Note 11, which is as of March 20, 2017), relating to the consolidated financial statements, which appear in this Form 10-K/A. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
| /s/ BDO USA, LLP | |
| Seattle, Washington | |
| March 20, 2017 |